Neurocrine Biosciences is presenting new research on VYKAT XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome (PWS), at the 2026 Foundation for Prader-Willi Research conference. Studies include real-world evidence on long-term safety and treatment outcomes, caregiver burden, and adverse events during treatment. This research aims to improve understanding and management of PWS, a rare genetic disorder causing extreme hunger and related health risks. The findings support Neurocrine's commitment to addressing unmet needs in the PWS community and enhancing patient care.
Neurocrine Biosciences (NBIX) is trading at USD 138.97 on Pluang as of Sep 30, 2026 19:17 WIB, which is closer to its 52-week low of USD 123.10 than its high of USD 185.50. Despite this, the stock shows a positive 1-day change of +0.45% and strong buying interest with 100% of Pluang order activity on the buy side. Investors hold NBIX for an average of 21 days on the platform, reflecting moderate-term engagement with the stock.
